Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neu Direction
NCT07729046Phase 2Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- Jul 2027
- Primary completion
- May 2032
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Standard of Care with Standard of Care + Neratinib (2 arms). Primary endpoints: Progression-Free Survival at 1 year and Treatment-related adverse events at 1 year. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07729046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729046.